Boehringer Ingelheim and GENEART Collaborate to Provide DNA Therapeutics and Vaccines
News Jun 24, 2008
Boehringer Ingelheim and GENEART announce their technology and sales collaboration. The collaboration includes a transfer of Boehringer Ingelheim technology to GENEART for the production and purification of plasmid DNA. The two partner companies also plan to closely collaborate in the distribution and marketing of their complementary services.
The collaboration offers system solution for the development of DNA-based pharmaceuticals. GENEART will use the Boehringer Ingelheim production and purification technology to deliver DNA-based agents for research, development and preclinical studies. Boehringer Ingelheim will produce the pharmaceuticals under cGMP (current Good Manufacturing Practice) conditions for the subsequent clinical phases and the market.
Customers in research and industry additionally benefit from GENEART's expertise in software-assisted design of gene sequences and from the production of these improved (optimized) sequences via gene synthesis. Optimized genes are essential for the improvement of product properties, such as for the enhancement of immunogenicity and safety of DNA based pharmaceuticals.
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019